In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 27 days of free consultation


Premature coronary artery disease among Egyptian patients with acute coronary syndrome; data from the cross-sectional cardio-risk project

Session Poster Session 6

Speaker Ashraf Reda

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P5487

Authors : ASHRAF Reda (Menoufia,EG), M Ashraf (Giza,EG), AHMED Bendary (Benha,EG), ATEF Elbahry (Port Foad,EG), ELSAYE Farag (Zagazig,EG), M Bendary (Giza,EG), M A Tabl (Benha,EG), TAMER Mostafa (Zagazig,EG), MOHEB Wadie (Mansoura,EG), M Selim (Giza,EG)

ASHRAF Reda1 , M Ashraf2 , AHMED Bendary3 , ATEF Elbahry4 , ELSAYE Farag5 , M Bendary6 , M A Tabl3 , TAMER Mostafa5 , MOHEB Wadie7 , M Selim2 , 1Menoufia faculty of medicine, Cardiology - Menoufia - Egypt , 2National Heart Istitute - Giza - Egypt , 3Benha Faculty of Medicine, Cardiology - Benha - Egypt , 4Cardiology center, Cardiology - Port Foad - Egypt , 5Zagazig University Hospitals, Cardiology - Zagazig - Egypt , 6National Cancer Institute, Cairo University, Biostatistics - Giza - Egypt , 7Mansoura University, Cardiology - Mansoura - Egypt ,

On behalf: Egyptian Association of Vascular biology and Atherosclerosis (EAVA)


Background. Egypt is the most populous country in Middle East and North Africa and has one of the highest rates of the cardiovascular (CV) deaths in the region. Despite governmental primary preventive efforts, very little is known about the prevalence and characteristics of premature coronary artery disease (CAD) among Egyptian patients with Acute Coronary syndrome (ACS).

Methods. From November 2015 to August 2018, data were collected from 3224 patients with ACS in 30 coronary care centers covering 11 governorates across Egypt, spanning the Mediterranean coast, Nile Delta, and Upper Egypt, with focus on premature CAD (defined as ACS before age 55 years in males and 65 years in females).

Results. The prevalence of premature CAD was 51%. They were significantly more females (35% versus 16%, P < 0.001) with significantly higher level of education. Risk factors’ (RFs) distribution showed a significantly higher prevalence of Type-1 Diabetes Mellitus (6% versus 4%, P = 0.005), obesity (42% versus 33%, P < 0.001) and smoking (50% versus 47%, P < 0.001) in patients with premature CAD when compared to others. Interestingly, rates of documented dyslipidemia were similar between groups (49% versus 47%, P = 0.45) with no significant difference in low density lipoprotein-cholesterol levels (131.7 ± 48.5 versus 130.2 ± 45.2 mg/dl, P = 0.4). Patients with premature CAD tended to present more frequently with ST-elevation myocardial infarction (STEMI) (50% versus 46%, P = 0.035), with higher rates of treatment using primary percutaneous coronary intervention compared to others (48% versus 44%, P = 0.04). They were also significantly less likely to receive Coronary Artery Bypass Graft (4% versus 6.5%, P = 0.003).

Conclusion. Prevalence of premature CAD is high among Egyptian patients with ACS, due to noticeably larger burden of traditional CV RFs especially smoking and possibly familial hypercholesterolemia. Much effort is still needed in screening for early detection of RFs of atherosclerosis together with more widespread adoption of diagnostic scores for FH such as Dutch Lipid Network criteria.

This content is currently on FREE ACCESS, enjoy another 27 days of free consultation


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are